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Background: We assessed whether lung sound analysis (LSA) is a valid measure of airway obstruction
and inﬂammation in patients with bronchial asthma during treatment with inhaled corticosteroids
(ICSs).
Methods: 63 good adherence patients with bronchial asthma and 18 poor adherence patients were
examined by LSA, spirometry, fractional exhaled nitric oxide (FeNO), and induced sputum. The
expiration-to-inspiration lung sound power ratio at low frequencies between 100 and 200 Hz (E/I LF)
obtained by LSA was compared between healthy volunteers and bronchial asthma patients. Next, post-
ICS treatment changes were compared in bronchial asthma patients between the good adherence pa-
tients and the poor adherence patients.
Results: E/I LF was signiﬁcantly higher in bronchial asthma patients (0.62 ± 0.21) than in healthy vol-
unteers (0.44 ± 0.12, p < 0.001). The good adherence patients demonstrated a signiﬁcant reduction in E/I
LF from pre-treatment to post-treatment (0.55 ± 0.21 to 0.46 ± 0.16, p ¼ 0.002), whereas the poor
adherence patients did not show a signiﬁcant change. The decrease of E/I LF correlated with the
improvement of FEV1/FVC ratio during the ICS treatment (r ¼ 0.26, p ¼ 0.04). The subjects with higher
pre-treatment E/I LF values had signiﬁcantly lower FEV1/FVC and V50,%pred (p < 0.001), and signiﬁcantly
higher FeNO and sputum eosinophil percentages (p ¼ 0.008 and p < 0.001, respectively).
Conclusions: The E/I LF measurement obtained by LSA is useful as an indicator of changes in airway
obstruction and inﬂammation and can be used for monitoring the therapeutic course of bronchial
asthma patients.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bronchial asthma is a chronic inﬂammatory disease character-
ized by airway inﬁltration of inﬂammatory cells, including eosin-
ophils, mast cells, macrophages, neutrophils, and lymphocytes, as
well as airway narrowing and increased bronchial hyper-
responsiveness (BHR).1Fukuoka National Hospital,
pan.
(T. Shimoda).
ety of Allergology.
rgology. Production and hosting by ElseLung sound auscultationwith a stethoscope is routinely performed
in clinical practice.2 Adventitious sounds that are audible on auscul-
tation, such as rhonchi and wheezes, play an important role in the
diagnosis of bronchial asthma.3,4 However, wheezes due to airway
obstructionarenotassensitiveadiagnostic indicatoraschanges in lung
sounds.When airway obstruction ismild, wheezes are often inaudible
on auscultationwith a stethoscope. Lung sound analysis (LSA) is useful
for examining the pathophysiology of bronchial asthma because it is
more sensitive than auscultationwith a stethoscope. Furthermore, LSA
is non-invasive and repeatable. We previously reported that the
expiration-to-inspiration sound power ratio in a low-frequency range,
between 100 and 195 Hz (E/I LF), was increased in bronchial asthma
patients with airway inﬂammation and obstruction.5vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
T. Shimoda et al. / Allergology International 66 (2017) 64e69 65In this study, we examined airway obstruction, inﬂammation,
and BHR to evaluate whether E/I LF is useful for monitoring the
effect of ICS therapy on the clinical course of bronchial asthma.
Methods
Subjects
Our study included 79 patients with mild persistent bronchial
asthma who were examined before and after 6 months of ICS ther-
apy (800 mg/day as CFC-BDP equivalent). Of these patients, 63 (82%)
used ICS regularly as prescribed (90e100% adherence; according to
the concordance rate between the asthma diary and the inhalation
usage)wereclassiﬁed in thegoodadherencegroup.14 subjects (18%)
used ICS irregularly (30e50% adherence) were classiﬁed in the poor
adherence group. There were 2 patients with 50e90% adherence
andnopatientswith less than 30% adherence. Bronchial asthmawas
diagnosed according to the Global Initiative for Asthma Guidelines.1
All subjects had to present values less than or equal to 8000mcg/mL
in a test of BHR to inhaled acetylcholine, and they had to have a
history of wheezing and/or dyspnea. At the initial visit, 80% of the
subjects showed positive reversibility (reversible with at least 12%
and 200 mL improvements in FEV1 after bronchodilator therapy),
whereas the remaining 20% had negative reversibility with normal
respiratory function at the visit and were diagnosed with bronchial
asthma based on positive BHR and medical history.
At the enrollment, no patients were treated with inhaled or sys-
temic corticosteroids. The use of anti-asthma drugs, including bron-
chodilators,wasdiscontinued forat least 24hprior to the examination.
Subjects with a history of chronic obstructive pulmonary disease, any
cardiovascular diseases, or with a current viral or bacterial infection
were excluded from the study. The healthy control subjects (n ¼ 27)
had no respiratory symptoms, no overt illnesses, and exhibited no
abnormalities in their lung function tests and chest radiographies. The
ethics committee of Fukuoka National Hospital approved the studyFig. 1. Sound spectrogram display of lung sounds in a patient (Easy LSA). The recorded so
frequency shown in Hz on the vertical axis and time on the horizontal axis. The sound intens
of inspiratory or expiratory position. Calculation of the average sound pressure level (dBSPprotocol (protocol No. 20-12), and all participants received verbal and
written study information before providing their informed consent.
Lung sound analysis
Lungsoundswere recorded for30sover thebaseof the left lung
using a hand-held microphone. The patients took a deep breath
through a disposablemouthpiece to synchronize their breath cycles
while the breath sounds were recorded. The recording system
consisted of an electro-stethoscope containing a wide-range audio
sensor thatwas adhered inside a diaphragm (Bio-Sound Sensor BSS-
01; Kenz Medico, Saitama, Japan), a signal processing system, and a
personal computer. The sensor had a band-pass ﬁlter range of
40e2500Hzanda sound-collecting ability in the40e2000Hz range.
The recorded sounds were analyzed using a sound spectrometer
(Easy LSA-2008; Nakano, Fukuoka National Hospital). The recorded
sounds were re-sampled to 10,000 Hz and analyzed by 1024-point
fast Fourier transformation (FFT) with 60% overlap into adjacent
segments, using a Hanning data window. The results are presented
as a sound spectrograph with frequencies in Hz on the vertical axis
and time on the horizontal axis. On the display, the vertical axis
displays the cycles per minute in kilohertz, and the horizontal axis
displays the time in seconds. The intensity (dBSPL) of the sound is
depicted by the color and brightness (Fig. 1). The recording system
was calibrated with a reference sound pressure (1 kHz; 94 dB
[0 dB ¼ 20 mPa]). We deﬁned low frequencies (LF) as frequencies of
100e200 Hz, and we determined inspiration sound pressure, expi-
ration soundpressure, and inspiration-to-expiration soundpressure
ratio in the low-frequency range (E/I LF). E/I LF data were converted
from logarithmic values (dBSPL) to real values.5
Measurement of ﬂowevolume curves
Lung function was measured using a spirometer (Chest Graph
HI-701, Chest M.I., Tokyo, Japan). The results are expressed as aund was analyzed by fast Fourier analysis and displayed as a spectrograph with the
ity is presented by color and brightness. Selected portion of the analysis. Selected range
L) at a low frequency (100e200 Hz).
Table 1
Patient characteristics.
BA (n ¼ 77) HV (n ¼ 27) p-Value
(BA vs. HV)
Mean ± SD Mean ± SD
Age (yr) 42.7 ± 13.8 38.5 ± 13.6 0.09
BMI 22.8 ± 3.4 22.0 ± 4.0 0.36
Male/Female 32/45 9/18 0.45
Duration (yr) 5.0 ± 7.8
Atopic/non-atopic 53/29
Non-smoker/ex- smoker/smoker 42/18/18 15/5/7 0.91
FEV1/FVC% 75.9 ± 9.4 84.9 ± 7.1 <0.0001
FEV1,%pred. 92.1 ± 14.1 101.2 ± 11.3 0.0015
V50,%pred. 66.6 ± 24.9 88.1 ± 17.2 <0.0001
E/I LF 0.55 ± 0.20 0.44 ± 0.12 0.0006
Fig. 2. Comparison of E/I LF among healthy subjects, bronchial asthma with sputum
eosinophils <3% and bronchial asthma with sputum eosinophils 3%. E/I LF is signif-
icantly higher in bronchial asthma with sputum eosinophils 3% than in bronchial
asthma with sputum eosinophils <3% or in healthy subjects.
T. Shimoda et al. / Allergology International 66 (2017) 64e6966percentage of the predicted values based on the relevant reference
standards.6
Measurement of the fractional exhaled nitric oxide (FeNO)
concentration
Following the guidelines published by American Thoracic Society
(ATS), FeNO was measured using the online single-breath method
and a fast response (0.02 s) chemiluminescence analyzer (Sievers
Nitric Oxide Analyzer NOA 280i, GE Analytical Instruments, Boulder,
CO,USA).5,7 Allmeasurementswere obtainedusing amouthpressure
of 16 cmH2O, corresponding to an expiratory ﬂow of 50 mL/s. The
FeNO concentrations were recorded as the average of 3 FeNO values.
Measurement of airway hyperresponsiveness to acetylcholine (Ach)
The challenge test was performed using standardized method-
ology. The subjects inhaled isotonic saline ﬁrst for 2 min from a
hand-held nebulizer (PARI BOY 038; PARI GmbH, Starnberg, Ger-
many). They then inhaled progressive doublings of the Ach con-
centration from 39 to 20,000 mcg/mL. The test was continued until
the FEV1.0 had decreased by >20%. BHR was expressed as the
provocative concentration of acetylcholine causing a 20% fall in
FEV1 (PC20). Subjects with a PC20 < 8000 mcg/mL were considered
to have positive BHR.8
Sputum induction and processing
The participants inhaled 5 mL 3% NaCl solution through an ul-
trasonic nebulizer to induce sputum collection.9 The subjects were
asked to cough during and after the inhalation and to expectorate
into empty containers. Sputum was induced over a 20-min period.
The sputum samples were processedwithin 30min according to
a method described by Metso et al.9 The sputum cells were sepa-
rated by centrifugation at 2000 g for 10 min. The cell suspension
was cytocentrifuged (Cytospin 3; Shandon, Astmoor, UK) onto mi-
croscope slides at 450 rpm for 6 min. The cytospin products from
the sputum were air-dried for 30 min and then stained using the
Giemsa staining method (Muto Pure Chemicals Co., Ltd., Tokyo,
Japan). At least 400 non-squamous cells were counted differen-
tially, including eosinophils, neutrophils, lymphocytes, macro-
phages, and ciliated epithelial cells. The results are expressed as the
percentages of the total non-squamous cell counts.
Statistical analysis
The data analysis was performed using JMP (Statistical Discov-
ery™ from SAS Institute, Cary, NC, USA). The Student's t-test was
used to compare E/I LF between healthy subjects and bronchial
asthma patients. The TukeyeKramer HSD test was used to compare
E/I LFamong thegroupwith sputumeosinophils<3%, thegroupwith
sputum eosinophils S3%, and healthy volunteers. To examine
changes by ICS treatment, Student's t-test was applied to compare
pre-treatment and post-treatment values between the good
adherence and poor adherence groups. The correlation between the
E/I LF change and the other factorswere also evaluated. A suitable E/I
LF cutoff value was determined using receiver operating character-
istic analysis.10 The good adherence group was stratiﬁed into two
subgroups based on the cutoff value, and a t-test was performed to
compare the subgroup with a pre-treatment E/I LF higher than or
equal to the cutoff to the subgroupwith a pre-treatment E/I LF below
the cutoff value. To analyze major factors inﬂuencing the pre-
treatment E/I LF value, variable selection was conducted in a step-
wisemannerwith a combination of forward and backward selection
techniques; a predictivemodelwas then constructed, and a nominallogistic regression analysis was performed. Finally, to investigate
factors associated with ICS-unresponsive E/I LF in the good adher-
ence group, subjects were stratiﬁed based on E/I LF reduction after
ICS therapy and compared using Student's t-test.
Results
Background characteristics of bronchial asthma patients and
healthy subjects before treatment
Age, body mass index (BMI), and sex were not signiﬁcantly
different between bronchial asthma patients and healthy subjects.
However, FEV1.0/FVC (%), FEV1.0,%pred and V50,%pred were signiﬁcantly
reduced in bronchial asthma patients compared with healthy
controls (p < 0.001, p¼ 0.002, and p < 0.001, respectively) (Table 1).
E/I LF was signiﬁcantly higher in bronchial asthma patients
(0.55 ± 0.20) compared with healthy subjects (0.44 ± 0.12,
p ¼ 0.0006) (Table 1). When bronchial asthma patients were
stratiﬁed into two subgroups according to sputum eosinophil per-
centages (<3% vs.3%) and comparedwith the healthy group, E/I LF
was signiﬁcantly higher in the bronchial asthma patient subgroup
with sputum eosinophils 3% (0.62 ± 0.21) than in the subgroup
with sputum eosinophils <3% (0.45 ± 0.16) or the healthy subject
group (p < 0.001). No signiﬁcant differences were noted between
the bronchial asthma subgroup with eosinophils <3% and the
healthy group (Fig. 2).
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good and poor adherence groups during ICS therapy
No signiﬁcant differences were observed in all parameters
before treatment between the good adherence and poor adherence
groups. In the good adherence group, FEV1.0/FVC (%), FEV1.0,%pred,
V50,%pred, and logPC20 values were signiﬁcantly increased
(p < 0.0001), and FeNO and the sputum eosinophil percentagewere
signiﬁcantly decreased after ICS therapy (p < 0.0001). However, the
poor adherence group did not show noticeable changes in any of
these parameters after the study treatment (Table 2).Changes in E/I LF values by ICS therapy in the good adherence and
poor adherence groups
There were no signiﬁcant differences in E/I LF values before
treatment between the poor and good adherence groups
(p ¼ 0.574). After ICS therapy, E/I LF values were signiﬁcantly
reduced in the good adherence group (p ¼ 0.002) but not in the
poor adherence group (p ¼ 0.345) (Fig. 3).Table 2
Comparison of data between before treatment and after treatment.
Good adherence
Before treatment After treatment
n mean ± SD mean ± SD p
FEV1/FVC(%) 63 75.8 ± 9.7 79.3 ± 6.4 <
FEV1,%pred 63 93.1 ± 14.4 99.1 ± 11.6 <
V50,%pred 63 65.9 ± 24.2 75.9 ± 22.8 <
logPC20 63 2.83 ± 0.50 3.33 ± 0.61 <
FeNO 58 71.1 ± 70.1 31.1 ± 24.0 <
Macrophages (%) in sputum 49 38.4 ± 22.3 48.0 ± 24.0
Neutrophils (%) in sputum 49 38.4 ± 22.3 44.0 ± 23.6
Eosinophils (%) in sputum 49 17.6 ± 22.7 3.7 ± 9.0 <
E/I LF 63 0.55 ± 0.21 0.46 ± 0.16
y Comparison of before treatment values at poor adherence and good adherence grou
Fig. 3. Change in E/I LF after ICS therapy. (A) In the good adherence group, post-treatment E/I
adherence group, post-treatment E/I LF values are not signiﬁcantly different from pre-treatThe correlations of the E/I LF changes with other factors by the ICS
treatment in good adherence patients
The change of E/I LF was correlated with the improvement of
FEV1.0/FVC (r ¼ 0.26, p ¼ 0.04) (Table 3).
Comparison of background factors, spirogram, PC20, FeNO, and
sputum cell counts between subgroups with pre-treatment E/I LF
0.50 vs. <0.50 in the good adherence group
A receiver operating characteristic analysis was performed using
the pre-treatment data from healthy subjects and bronchial asthma
patients with airway inﬂammation to investigate the discrimina-
tion power and cutoff of E/I LF. Based on the results, when the area
under the curve was 0.76 and the E/I LF point on the ROC curve
closest to (0, 1) was 0.50 with a sensitivity of 0.71 and a speciﬁcity
of 0.69, then the E/I LF cutoff of 0.50 was established for further
analysis. In the good adherence group, the subgroup with a pre-
treatment E/I LF  0.50 included more males than the subgroup
with a pre-treatment E/I LF < 0.50 (p ¼ 0.049). The higher E/I LF
subgroup also had a signiﬁcantly lower FEV1/FVC (%) and V50,%predPoor adherence
Before treatment After treatment y
n mean ± SD mean ± SD p
0.0001 14 76.6 ± 7.7 79.1 ± 7.0 0.12 0.34
0.0001 14 87.9 ± 12.3 91.7 ± 12.5 0.19 0.42
0.0001 14 69.8 ± 28.8 70.3 ± 15.2 0.93 0.36
0.0001 14 2.85 ± 0.80 3.22 ± 0.67 0.053 0.83
0.0001 13 83.1 ± 75.4 71.9 ± 65.1 0.56 0.67
0.003 10 40.8 ± 23.6 45.5 ± 20.8 0.69 0.87
0.12 10 35.0 ± 23.6 38.3 ± 16.6 0.69 0.98
0.0001 10 18.1 ± 29.1 13.1 ± 15.6 0.65 0.96
0.002 63 0.55 ± 0.18 0.49 ± 0.17 0.35 0.92
p.
LF values are signiﬁcantly reduced compared with pre-treatment levels. (B) In the poor
ment values.
Table 3
The relation between the change of E/I LF and the changes of other factors.
DE/I LF
vs. factors r p Values
DFEV1.0/FVC(%) 0.26 0.04
DFEV1.0,%pred 0.12 0.36
DV50,%pred 0.18 0.16
DV25,%pred 0.07 0.58
DlogPC20 0.09 0.50
DFeNO 0.01 0.95
DMacrophage 0.02 0.90
DNeutrophils 0.10 0.51
DEosinophils 0.07 0.61
Table 4B
Logistic regression analysis (Divided into >0.50 and 0.50 pre-treatment E/I LF
values).
Estimate SE Chi square p (Prob > ChiSq)
Age 0.008 0.033 0.06 0.808
Sex [F] 0.605 0.448 1.82 0.177
Smoking (Pack-years) 0.033 0.032 1.09 0.297
FEV1/FVC% 0.125 0.059 4.44 0.035
FEV1,%pred. 0.029 0.035 0.68 0.410
logPC20 0.250 0.953 0.07 0.793
Eosinophils (%) in sputum 0.067 0.032 4.49 0.034
Table 5
Comparison of the background by E/I LF > 0.50.
T. Shimoda et al. / Allergology International 66 (2017) 64e6968(p < 0.001), as well as a signiﬁcantly higher FeNO and sputum
eosinophil percentage (p ¼ 0.008 and p < 0.001, respectively)
(Table 4A).
In a model search performed to predict factors that affect the
pre-treatment E/I LF value, the sputum eosinophil percentage had
the most profound effect on the pre-treatment E/I LF value
(p ¼ 0.034), followed by FEV1/FVC(%) (p ¼ 0.035) (Table 4B).
Investigation of factors responsible for ICS-unresponsive E/I LF in the
good adherence subgroup with a pre-treatment E/I LF  0.50
When the subjects in the good adherence group with a pre-
treatment E/I LF  0.5 were stratiﬁed into subjects whose E/I LF
decreased after ICS treatment (responders) and subjects without E/I
LF reduction (non-responders), the non-responders showed a sig-
niﬁcant elevation in sputum neutrophil percentages after ICS
therapy compared with the responders (p ¼ 0.049) (Table 5).
Discussion
We found that the LSA may be useful to deduce the patient ICS
adherence and the lung function improvement, however, it is not a
speciﬁc index to the airway eosinophilic inﬂammation change.
Lung sounds are generated in areas closer to large airways. The
pitch and strength of normal lung sounds are proportional to the
square of the airﬂow velocity.11 Lung sounds attenuate in propor-
tion to the distance squared from the sound source, and high-
pitched tone sounds are not transmitted in alveolar areas that are
located far from the sound source. In asthmatic patients, the fre-
quency and strength of lung sounds are modiﬁed due toTable 4A
Patient characteristics of good adherence group (Divided into >0.50 and 0.50 pre-
treatment E/I LF values).
E/I LF  0.50 E/I LF < 0.50 p Values
(n ¼ 37) (n ¼ 26)
Age (yr) 40.0 ± 11.2 45.8 ± 14.3 0.076
BMI 22.7 ± 2.8 23.3 ± 4.0 0.53
Male/Female 19/18 7/19 0.049
Duration (yr) 4.3 ± 7.5 4.5 ± 7.2 0.92
Atopic/non-atopic 22/15 17/9 0.633
Non-smoker/ex-/smoker 21/9/7 14/5/7 0.725
FEV1.0/FVC% 72.3 ± 10.5 80.7 ± 5.9 0.0002
FEV1.0,%pred. 90.5 ± 16.4 96.7 ± 10.1 0.072
V50,%pred. 57.0 ± 22.6 78.5 ± 20.7 0.0003
logPC20 2.76 ± 0.48 2.93 ± 0.52 0.19
FeNO 99.7 ± 78.1 44.0 ± 73.8y 0.008
Macrophages (%) in sputum 31.2 ± 17.6z 49.7 ± 20.7x 0.002
Neutrophils (%) in sputum 37.5 ± 21.7z 35.1 ± 24.0x 0.717
Eosinophils (%) in sputum 27.6 ± 26.2z 7.4 ± 13.8x 0.0006
y n ¼ 23.
z n ¼ 32.
x n ¼ 21.ﬂuctuations in respiratory ﬂow and airway damage caused by
inﬂammation.12 In broncho-provocation tests, acute airway nar-
rowing causes an increase in the frequency and intensity of lung
sounds.12e17 Fiz et al. reported a greater decrease in the frequency
of wheezing during maximal forced exhalation after bronchodila-
tion in asthmatics compared with normal controls.18 Shreur et al.
has suggested LSA can detect differences in the pathophysiology of
airway narrowing in asthma.19
We observed higher E/I LF values in bronchial asthma patients
with obvious airway inﬂammation compared with healthy people
and asthmatic patients without airway inﬂammation. Our previ-
ously proposed LSA, which uses E/I LF as an index of inﬂammation
and obstruction in asthmatic patients, is useful, simple and
noninvasive.4 Habukawa et al. has reported that LSA is useful for
evaluating the impact of medications on bronchial asthma con-
trol.20 Improving treatment adherence is a complex task.21 In the
present study, a signiﬁcant improvement in airway obstruction
with reduced airway inﬂammation and hyperresponsiveness was
observed in the good adherence group but not in the poor adher-
ence group. Similarly, evaluation of the changes in E/I LF after ICS
therapy conﬁrmed a reduction in E/I LF in the good adherence
group but not in the poor adherence group and the decrease of E/I
LF was related with the improvement of FEV1/FVC during the ICS
medication.
The subgroup with a higher pre-treatment E/I LF had a higher
degree of airway obstruction and eosinophilic airway inﬂamma-
tion. In the good adherence group, 79% of subjects with higher pre-
treatment E/I LF values demonstrated E/I LF reduction after ICS
treatment. However, the remaining 21% did not show a reduction inResponder Non-responder p Values
(n ¼ 29) (n ¼ 8)
Age (yr) 45.2 ± 14.8 48.0 ± 13.3 0.618
BMI 22.7 ± 2.9 22.9 ± 2.7 0.881
Male/Female 13/16 6/2 0.13
Duration (yr) 4.3 ± 7.8 4.3 ± 6.7 0.98
Atopic/non-atopic 19/10 3/5 0.153
Non-smoker/ex-/smoker 18/6/5 3/3/2 0.45
DFEV1.0/FVC% 5.16 ± 8.65 6.45 ± 5.50 0.616
DFEV1.0,%pred. 6.82 ± 12.89 11.16 ± 6.77 0.213
DV50,%pred. 11.39 ± 18.27 13.64 ± 15.86 0.737
DlogPC20 0.46 ± 0.61 0.41 ± 0.71 0.958
Dlog FeNO 0.32 ± 0.32y 0.46 ± 0.25 0.244
D Macrophages (%) in sputum 12.22 ± 23.64z 8.580 ± 35.67x 0.821
D Neutrophils (%) in sputum 2.13 ± 26.92z 24.50 ± 20.28x 0.049
D Eosinophils (%) in sputum 15.07 ± 14.60z 32.33 ± 33.91x 0.056
Responder: E/I LF is decrease by treatment, Non-responder: E/I LF is not decrease by
treatment.
D, Amount of changes.
y n ¼ 28.
z n ¼ 23.
x n ¼ 6.
T. Shimoda et al. / Allergology International 66 (2017) 64e69 69E/I LF. We found that the responder group had a reduced sputum
eosinophil percentage, whereas the non-responder group had a
reduced sputum eosinophil percentage and an increased neutro-
phil percentage also. This reason may be that the neutrophilic
airway inﬂammation has been shown to respond poorly to
steroids.22
The present ﬁndings indicate that E/I LF increases in both
eosinophilic and neutrophilic types of airway inﬂammation.
Among bronchial asthma patients with high E/I LF values who
received ICS treatment, those who showed a reduction in E/I LF
were likely to have experienced an improvement in eosinophilic
airway inﬂammation that did not involve neutrophils. Table 5
suggests the E/I LF decrease was also caused by neutrophilic
inﬂammation decrease. The patients with high E/I LF before treat-
ment had high level of both of eosinophilic and neutrophilic
inﬂammation. E/I LF may be possible to be an index of the bronchial
inﬂammation and obstruction level in asthmatic patients, but is not
speciﬁed to the eosinophilic inﬂammation.
In conclusion, E/I LF is useful for evaluating the efﬁcacy of ICS
therapy in patients with mild persistent bronchial asthma. We
anticipate that E/I LF could be applied as a new noninvasive indi-
cator method of bronchial asthma control level.
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